Free Trial

Rocket Pharmaceuticals (RCKT) 10K Form and Latest SEC Filings 2026

Rocket Pharmaceuticals logo
$3.54 -0.07 (-1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$3.56 +0.02 (+0.71%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Rocket Pharmaceuticals SEC Filings & Recent Activity

Rocket Pharmaceuticals (NASDAQ:RCKT) has submitted 476+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Rocket Pharmaceuticals's financial statements. The most recent filing was a Form 8-K submitted on April 28, 2026.

Form 4
ROCKET PHARMACEUTICALS, INC. Reports Ownership Change on Feb. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Rocket Pharmaceuticals Files Current Report on Apr. 28, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Rocket Pharmaceuticals Files Annual Report on Feb. 26, 2026

The 10-K contains Rocket Pharmaceuticals's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Rocket Pharmaceuticals SEC Filing History

Browse Rocket Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/28/2026 6:34 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/27/2026 8:42 AM
Rocket Pharmaceuticals (1281895) Subject
Form SC TO-I
04/06/2026 3:06 PM
Rocket Pharmaceuticals (1281895) Filer
Form DEF 14A
04/06/2026 3:10 PM
Rocket Pharmaceuticals (1281895) Filer
Form DEFA14A
04/06/2026 3:11 PM
Rocket Pharmaceuticals (1281895) Filer
Form ARS
04/03/2026 7:30 AM
Rocket Pharmaceuticals (1281895) Subject
Form SC TO-C
03/27/2026 6:32 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2026 7:16 PM
Rocket Pharmaceuticals (1281895) Filer
Form PRE 14A
03/10/2026 11:15 PM
Rocket Pharmaceuticals (1281895) Filer
Form EFFECT
03/10/2026 4:19 PM
Rocket Pharmaceuticals (1281895) Filer
Form 424B5
03/10/2026 4:24 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/02/2026 3:17 PM
Rocket Pharmaceuticals (1281895) Filer
Form S-3
Registration statement under Securities Act of 1933  
02/26/2026 3:06 PM
Rocket Pharmaceuticals (1281895) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/18/2026 4:33 PM
Rocket Pharmaceuticals (1281895) Issuer
Shah Gaurav (1725922) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 4:38 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 4:42 PM
Rocket Pharmaceuticals (1281895) Issuer
Wilson Martin (1704342) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 3:10 PM
MAVERICK CAPITAL LTD (934639) Filed by
Rocket Pharmaceuticals (1281895) Subject
Form SCHEDULE 13G/A
02/13/2026 2:53 PM
Rocket Pharmaceuticals (1281895) Subject
Schwartz Jonathan David (1726398) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/13/2026 2:55 PM
Rocket Pharmaceuticals (1281895) Subject
Shah Gaurav (1725922) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/30/2026 1:46 PM
Rocket Pharmaceuticals (1281895) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
01/06/2026 3:05 PM
Bjork Elisabeth (1810406) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 3:05 PM
Rocket Pharmaceuticals (1281895) Issuer
Wilson Martin (1704342) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 3:05 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 3:05 PM
Rocket Pharmaceuticals (1281895) Issuer
Shah Gaurav (1725922) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 3:05 PM
Rocket Pharmaceuticals (1281895) Issuer
Schwartz Jonathan David (1726398) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 2:16 PM
Rocket Pharmaceuticals (1281895) Subject
Wilson Martin (1704342) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2025 2:16 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2025 2:26 PM
Rocket Pharmaceuticals (1281895) Subject
Shah Gaurav (1725922) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2025 3:01 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/14/2025 11:29 AM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/14/2025 6:09 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/08/2025 2:39 PM
Rizvi Syed Ali-aamir (1897621) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 7:24 PM
Fong Peter (2062181) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/03/2025 7:33 PM
Fong Peter (2062181) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 3:30 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 6:02 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 4:19 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/23/2025 3:21 PM
Rocket Pharmaceuticals (1281895) Issuer
RTW INVESTMENTS, LP (1493215) Reporting
WONG RODERICK (1493280) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2025 5:33 PM
Rizvi Syed Ali-aamir (1897621) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/17/2025 3:15 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2025 3:22 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2025 3:15 PM
Rocket Pharmaceuticals (1281895) Issuer
Schwartz Jonathan David (1726398) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2025 3:18 PM
Rocket Pharmaceuticals (1281895) Issuer
Wilson Martin (1704342) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 7:54 PM
Bjork Elisabeth (1810406) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/25/2025 3:05 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2025 4:00 PM
Rocket Pharmaceuticals (1281895) Issuer
Shah Gaurav (1725922) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 4:00 PM
Rocket Pharmaceuticals (1281895) Issuer
Wilson Martin (1704342) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 4:00 PM
Rocket Pharmaceuticals (1281895) Issuer
Schwartz Jonathan David (1726398) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 4:00 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 6:11 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/18/2025 3:35 PM
Rocket Pharmaceuticals (1281895) Issuer
Wilson Martin (1704342) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025 3:35 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025 3:35 PM
Rocket Pharmaceuticals (1281895) Issuer
Schwartz Jonathan David (1726398) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025 2:24 PM
Rocket Pharmaceuticals (1281895) Subject
Wilson Martin (1704342) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2025 2:10 PM
Rocket Pharmaceuticals (1281895) Subject
Schwartz Jonathan David (1726398) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2025 2:10 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 4:44 PM
Rocket Pharmaceuticals (1281895) Subject
Schwartz Jonathan David (1726398) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 4:47 PM
Rocket Pharmaceuticals (1281895) Subject
Wilson Martin (1704342) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 4:55 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 7:00 AM
MAVERICK CAPITAL LTD (934639) Filed by
Rocket Pharmaceuticals (1281895) Subject
Form SCHEDULE 13G/A
07/24/2025 6:10 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/17/2025 6:46 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/11/2025 3:38 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2025 3:05 PM
Ondrey Aaron (1991078) Reporting
Rocket Pharmaceuticals (1281895) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 2:17 PM
Ondrey Aaron (1991078) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/18/2025 3:52 PM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2025 6:43 PM
Rocket Pharmaceuticals (1281895) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
05/27/2025 6:40 AM
Rocket Pharmaceuticals (1281895) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/20/2025 2:13 PM
Patel Kinnari (1725929) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 2:15 PM
Rocket Pharmaceuticals (1281895) Subject
Shah Gaurav (1725922) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 2:17 PM
Rocket Pharmaceuticals (1281895) Subject
Schwartz Jonathan David (1726398) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 2:21 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 2:29 PM
Rocket Pharmaceuticals (1281895) Subject
Wilson Martin (1704342) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/16/2025 2:32 PM
Militello John (1662170) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/16/2025 2:18 PM
Patel Kinnari (1725929) Reporting
Rocket Pharmaceuticals (1281895) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/07/2025 8:59 AM
Rocket Pharmaceuticals (1281895) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
05/07/2025 9:02 AM
Rocket Pharmaceuticals (1281895) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Rocket Pharmaceuticals SEC Filings - Frequently Asked Questions

Rocket Pharmaceuticals (RCKT) has submitted 476+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Rocket Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Rocket Pharmaceuticals's financial statements page.

The most recent filing was a Form 8-K submitted on April 28, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:RCKT) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners